Compare FIVN & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIVN | AAPG |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2014 | 2024 |
| Metric | FIVN | AAPG |
|---|---|---|
| Price | $32.90 | $17.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 5 |
| Target Price | $26.06 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 3.4M | 4.3K |
| Earning Date | 04-30-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 364.71 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,149,088,000.00 | N/A |
| Revenue This Year | $11.39 | $290.34 |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | $129.20 | ★ N/A |
| Revenue Growth | ★ 10.28 | N/A |
| 52 Week Low | $13.29 | $16.36 |
| 52 Week High | $34.58 | $45.90 |
| Indicator | FIVN | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 61.21 | 42.32 |
| Support Level | $17.59 | $16.62 |
| Resistance Level | $34.58 | $18.17 |
| Average True Range (ATR) | 2.01 | 0.53 |
| MACD | -0.10 | -0.06 |
| Stochastic Oscillator | 73.51 | 33.34 |
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.